AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 80 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 80 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 160 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 160 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 240 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 240 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 320 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 320 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 560 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 560 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous
Study NCT02660801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
Study NCT02660801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
Study NCT05228327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint treatment
Description: Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
Study NCT05228327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Masticatory muscle injection
Description: Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
Study NCT05228327 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of occlusal splint and masticatory muscle injection treatments
Description: Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
Study NCT00408148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Undistinguishable placebo tablets
Study NCT00408148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: White film-coated, for oral administration containing 20 mg of active rimonabant
Study NCT03776825 — intervention group
Intervention type: DEVICE
Intervention: Permacol Paste
Description: Permacol Paste Injection
Study NCT00742092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
Study NCT00742092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
Study NCT01870193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine, cysteine (as n-acetylcysteine), alanine
Description: Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months
Study NCT01870193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glycine, cysteine (as n-acetylcysteine), alanine
Description: Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months
Study NCT02756754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
Study NCT04701463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate
Description: 2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
Study NCT04701463 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric formula
Study NCT02924896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast
Study NCT00585351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced notification
Description: Advanced notification of study via faxed consent to local Emergency Room (ER)
Study NCT00585351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No advanced notification
Description: No advanced notification of study via faxed consent to local Emergency Room (ER)
Study NCT00585351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No advanced notification
Description: No advanced notification of study via faxed consent to local Emergency Room (ER)
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters
Study NCT03169777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03169777 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)
Study NCT01421823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 weeks local treatment with placebo ointment
Study NCT00806741 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head
Study NCT00806741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT00806741 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT00806741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while blood flow is measured
Study NCT04144543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
Study NCT04144543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking
Description: The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
Study NCT04144543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise+Facilitated Tucking
Description: The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT00882778 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
Study NCT01691495 — intervention group
Intervention type: DRUG
Intervention: Fondaparinux
Description: Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
Study NCT04523272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT00806741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while blood flow is measured
Study NCT03601949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SInergy Cooled Radiofrequency
Description: ablation of low back pain
Study NCT03601949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: physical therapy, medications, lifestyle changes
Study NCT04523272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study NCT04523272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study NCT01232686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online disease surveillance data access
Description: In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
Study NCT03268759 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: Observation of neural markers of reward processing
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03169777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study NCT04509609 — intervention group
Intervention type: OTHER
Intervention: Exon 3 truncating mutation
Description: Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
Study NCT02924896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast
Study NCT02754687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
Study NCT03601949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: physical therapy, medications, lifestyle changes
Study NCT02411214 — intervention group
Intervention type: OTHER
Intervention: survey
Description: questionnaire survey sent by regular mail for 3 groups
Study NCT02772445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STROKE-CARE
Description: In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
Study NCT04206384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultimate Contour Body Sculpting Device
Study NCT01600235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
Study NCT06176378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional pulpotomy
Description: After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
Study NCT06176378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser pulpotomy
Description: after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
Study NCT04788277 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of urine samples
Study NCT02112578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: 25 mg, 3 times per day up to 30 days
Study NCT02112578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: 50 mg, 3 times per day up to 30 days
Study NCT04509609 — intervention group
Intervention type: OTHER
Intervention: Any other mutation in SGBC gene
Description: Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
Study NCT02563483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga and compassion meditation program
Description: 25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
Study NCT04330248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
Study NCT04330248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
Study NCT03248856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: Intratympanic administration
Study NCT02924896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast
Study NCT04175795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Personal Brain Health Dashboard
Description: The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors.
Study NCT01820559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT01820559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 1200 mg
Description: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
Study NCT01820559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 800 mg
Description: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.